Philipp Metzger - Publications

RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model.

Journal: Molecular cancer therapeutics

Published: October 29, 2025

Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 13, 2021

OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.

Journal: Science immunology

Published: August 10, 2020

Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.

Journal: The Journal of experimental medicine

Published: July 18, 2020

Experimental approach to nasal septal cartilage regeneration with adipose tissue-derived stem cells and decellularized porcine septal cartilage.

Journal: Xenotransplantation

Published: May 21, 2020

T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.

Journal: Nature biomedical engineering

Published: May 11, 2020

A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosis-Like Hyperinflammation.

Journal: The journal of allergy and clinical immunology. In practice

Published: March 27, 2020

Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.

Journal: Cancer immunology, immunotherapy : CII

Published: December 31, 2019

Correction to: Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.

Journal: Journal for immunotherapy of cancer

Published: December 18, 2019

IFN Regulatory Factor 4 Controls Post-ischemic Inflammation and Prevents Chronic Kidney Disease.

Journal: Frontiers in immunology

Published: June 25, 2019

Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.

Journal: Radiation oncology (London, England)

Published: May 15, 2019

Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.

Journal: Journal for immunotherapy of cancer

Published: April 01, 2019